To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...
Expert discusses how the prevalence of chronic kidney disease (CKD), as reflected by decreased estimated glomerular ...
Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens. Current treatment options for EGFR-mutant lung cancer ...
The full manuscript, titled “Enozertinib is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-small Cell Lung Cancer with EGFR Exon 20 and Atypical Mutations,” is available online at Cancer ...
Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...
Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...
BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback